Apollo Hospitals Enterprise · tone and specificity signals across the available quarters.
Language signals
We are pleased to commence FY2024 on a positive note with a strong Q1, characterized by continued growth in top line, improved volumes and payer mix, meaningful network additions, and further growth in the user base for our digital offerings.
The business is on track to achieve operational break-even in Q4 2024.
I think we should be able to hit the target of 3,000. Very early in the stage to kind of say that, you know, we'll not be able to hit.
We are delighted to report a strong start to fiscal year FY 2024-25, with our performance in quarter 1 FY 2025. We have seen robust performance across all of our business segments, despite the headwinds of election cycles and heat waves, culminating in strong revenue growth and improved profitability on a year-on-year basis.
The volume growth has been very intentional. We have driven that volume growth very intentionally. We've been intentional about the markets that we have driven that volume growth in, so that's why we believe it is sustainable as well.
We are reasonably confident that the combination of growth in a calibrated way, along with the break-even, goal that we have sort of given guidance to, we will stick to it.
We are well on track to achieve breakeven in the digital business by the end of this fiscal.
Incremental players coming in with aggressive strategies, in my mind, will expand the digital market and give a greater amount of trials.
We have a plan to move it to 25%. As we look at the losses from new hospitals, total impact over a two-year period could maximum be around INR 150 crore.
We are on track to achieve operational break-even in quarter four FY 2024.
We are seeing that there is a higher demand that we are witnessing for both semi-private and private.
We are on track to add 2,300 beds across eight locations at a cost of INR 3,400 crore in the next three financial years.
We are well poised to commission six facilities with over 1,400 operational beds in key strategic metro markets like NCR, Hyderabad, Kolkata, Pune, and Bangalore in FY 26.
Apollo HealthCo has reported its first-ever quarterly profit with a PAT of INR 19 crore, contributing to a sharp improvement in the consolidated PAT on a year-on-year basis.
We are reasonably confident that the GMV will come back, but on a more sustainable basis. Whether it's a 50% growth or not, we will sort of reserve comments, but from a profitability perspective, we will hold on to our EBITDA profitability that we are committed for.
We are quite confident that we will get back into 13% growth. Bangladesh, at least 60%, has started coming back in October, and we believe that we will mitigate the impact of losing one territory.
Our internal target is to get all of them to break even in 12 months.
All the three lines of businesses that I spoke about, pharmacy, diagnostics, and consult business, at a CM1 level, has turned positive, each one of them at an individual level.
We have delivered ahead of time on a bit of break-even for Apollo HealthCo. I'm sure we will continue to deliver on our strategic intent.
Internally, we would like to believe that there is an opportunity to increase the margins by at least 200 basis points over the next few quarters.
Our entire growth is being led by volume. We are bullish that we'll be able to sustain at 20% kind of growth levels.
Our results reflect an all-around growth, with all three business segments reporting mid-teens revenue growth.
We will operate on both levels, but I would request all of you to bear with us for one more quarter.
We are quite hopeful that we should be able to break even in less than 12 months.
We are pleased to report a strong performance within what is typically a seasonally weak quarter.
Our discount is stabilizing. Our average order value has gone up by almost INR 111 net of the GST, which has a positive impact on our unit economics.
We will continue to be able to maintain margins. We are carefully balancing the EBITDA deterioration in our new hospitals with how we are managing our existing hospitals.
We are looking at a growth of beyond 15%. This growth will be driven by volume.
Our target is to get to 25%. That's what we have as internal targets.
The Supreme Court said that hospital rates are a function of market rates... it was a very good outcome for the private sector.
We crossed INR 20,000 crore in consolidated revenue and came in at INR 21,794 crore. Alongside, healthcare services revenue crossed the milestone of INR 10,000 crore and came in at INR 11,147 crore.
We are on track to operationalize our previously announced facilities in Gurgaon, Pune, Kolkata, and Hyderabad later this fiscal year.
Our trajectory to continuously reduce costs at the same time increase our net revenue on the pharmacy business, which effectively drives the turnaround, is on course.